Imagion Biosystems Limited has lodged Appendix 4G “Key to Disclosures, Corporate Governance Council Principles and Recommendations” with the Australian Securities Exchange. Read Appendix 4G and Corporate Governance Statement.
Quarterly Activity Report – Quarter ending 31 December 2023
January 31, 2024
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal